Investments
4
Want to inform investors similar to GSM Fund about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest GSM Fund News
Dec 2, 2014
Announces Completion of Reverse Split and Name Change TEMPE, Ariz., Dec. 1, 2014 /PRNewswire/ -- GSM Fund Group Inc. (OTC: IFNXD: PK) (the "Company") announced today it has recently changed its corporate name from "InfoLinx Communications Ltd." to "GSM Fund Group Inc." and also completed a 1:100 reverse split of its outstanding shares of common stock. On November 7, 2014, the Company's Board of Directors and shareholder holding a majority of the Company's outstanding voting rights approved changing the Company's name to GSM Fund Group Inc. and to effect a 100:1 reverse split. Thereafter, the Company filed a Certificate of Amendment with the Nevada Secretary of State to take such actions and submitted a Notice of Corporate Action to FINRA. On November 20, 2014, FINRA informed the Company that such corporate actions would take effect at the open of business on November 21, 2014. The Company also changed its ticker symbol to GSMF, which will take effect twenty (20) business days from November 21, 2014. As a result of the aforementioned reverse split, the Company's capital stock structure and information is as follows: Trading Symbol: IFNXD (for 20 business days starting on November 21, 2014; thereafter, the symbol shall be GSMF). Title and Class of
GSM Fund Investments
4 Investments
GSM Fund has made 4 investments. Their latest investment was in Elcelyx Therapeutics as part of their Series E on October 10, 2015.

GSM Fund Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
10/1/2015 | Series E | Elcelyx Therapeutics | $40M | No | 2 | |
2/19/2015 | Series D - II | |||||
2/21/2014 | Series D | |||||
2/14/2013 | Series C |
Date | 10/1/2015 | 2/19/2015 | 2/21/2014 | 2/14/2013 |
---|---|---|---|---|
Round | Series E | Series D - II | Series D | Series C |
Company | Elcelyx Therapeutics | |||
Amount | $40M | |||
New? | No | |||
Co-Investors | ||||
Sources | 2 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.